Pfizer and BioNTech report that omicron-based vaccines improve their response against the variant

Pfizer and BioNTech report that omicron-based vaccines improve their response against the variant

A version of the vaccine that contained both the redesigned and original vaccines caused a 9.1- and 10.9-fold increase, they noted.

The results came from a trial with 1,234 people aged 56 and older. The vaccines were well tolerated by the participants, the companies said.

The companies noted that early laboratory studies suggest that both omicron-modified candidates neutralize the BA.4 and BA.5 subvariants that have been circulating more recently, although to a lesser extent than for BA.1, with approximately 3-fold lower titers.

The companies say they continue to collect data on the performance of the boosters against the strains that have circulated most recently.

Moderna has also manufactured a redesigned vaccine targeting the BA.1 subvariant of omicron. The company said its updated vaccine worked well against the latest omicron subvariants, and it was moving forward with plans to apply for regulatory approval.